Perspective Therapeutics, Inc. has announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024, where the company will present information on sponsored studies of its assets. The company will showcase its activities with vmt-α-net and other promising therapies, highlighting its commitment to advancing care for patients battling challenging tumor types.
The abstract describing Perspective’s trial in progress of the phase 1/2a dose escalation study (NCT05636618) in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapies stated the trial’s status as of January 15, 2024. Updates on this trial as of March 7, 2024, were provided during the company’s investor update on March 18, 2024. The study, in conjunction with the phase 0 imaging study (NCT05111509), would inform the recommended phase 2 dose of [212pb]vmt‑α‑net.
In collaboration with independent investigators, Perspective is evaluating dosimetry and the applicability of patient-specific dosing as determined by a target renal absorbed dose for [212pb]vmt-α-net. An abstract reported pooled data from ten patients recruited in the company’s sponsored phase 0 imaging study and an investigator-sponsored absorbed dose escalation study. The company has been informed that updated results from the investigator-initiated trial of [212pb]vmt-α-net in India have been accepted for presentation by the SNMMI conference. The update includes results from 12 patients at a later data cutoff date than previous presentations.
The company will also present preclinical data for [212pb]vmt01, a targeted α-particle radionuclide therapy targeting the melanocortin 1 receptor (MC1R), used in combination with immune checkpoint inhibitors in diverse murine melanoma models with high, mid, and low expressions of MC1R. The ongoing phase 1/2a study of [212pb]vmt01 is being amended to evaluate the safety and tolerability of Perspective’s [212pb]vmt01 in combination with the immune checkpoint inhibitor nivolumab in patients with histologically confirmed melanoma and MC1R-positive imaging scans.
Furthermore, the company will introduce [203/212pb]-psv-359, a novel cyclic peptide developed to target fibroblast activation protein alpha (FAP), a protein abundantly expressed by cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, is pioneering advanced treatment applications for cancers throughout the body. The company's melanoma (vmt01) and neuroendocrine tumor (vmt-α-net) programs have entered phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at leading academic institutions. The company has also developed a proprietary 212pb generator to secure key isotopes for clinical trial and commercial operations. Today the company's shares have moved -6.4% to a price of $1.52. If you want to know more, read the company's complete 8-K report here.
